Literature DB >> 12525727

The spectrum of neuropathy in diabetes and impaired glucose tolerance.

C J Sumner1, S Sheth, J W Griffin, D R Cornblath, M Polydefkis.   

Abstract

OBJECTIVE: To compare the neuropathy associated with impaired glucose tolerance (IGT) and diabetes mellitus (DM) determined by oral glucose tolerance testing (OGTT).
METHODS: Patients with peripheral neuropathy of unknown cause were prescribed OGTT. Duration of neuropathic symptoms, neuropathic pain, neuropathy classification, nerve conduction test results, and intraepidermal nerve fiber densities (IENFD) were compared between IGT and DM groups.
RESULTS: Seventy-three patients completed OGTT; 41 (56%) had abnormal results. Of these 41 patients, 26 had IGT and 15 had DM. Patients with IGT had less severe neuropathy than patients with diabetes, as measured by sural nerve amplitudes (p = 0.056), sural nerve conduction velocities (p = 0.03), and distal leg IENFD (p = 0.01). Patients with IGT had predominantly small fiber neuropathy, compared to patients with DM (p = 0.05), who had more involvement of large nerve fibers.
CONCLUSIONS: The neuropathy associated with IGT is milder than the neuropathy associated with DM. Small nerve fibers are prominently affected and may be the earliest detectable sign of neuropathy in glucose dysmetabolism. OGTT is appropriate in patients with idiopathic neuropathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525727     DOI: 10.1212/wnl.60.1.108

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  190 in total

Review 1.  Contemporary insights into painful diabetic neuropathy and treatment with spinal cord stimulation.

Authors:  Kai McGreevy; Kayode A Williams
Journal:  Curr Pain Headache Rep       Date:  2012-02

2.  Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.

Authors:  Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Yury Maksimchyk; Tamara M Kuchmerovska; Jerry L Nadler; Irina G Obrosova
Journal:  Exp Neurol       Date:  2011-04-16       Impact factor: 5.330

3.  Thermal threshold: research study on small fiber dysfunction in distal diabetic polyneuropathy.

Authors:  Pedro Jimenez-Cohl; Carlos Grekin; Cristian Leyton; Claudio Vargas; Roberto Villaseca
Journal:  J Diabetes Sci Technol       Date:  2012-01-01

4.  Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice.

Authors:  Lawrence Coppey; Eric Davidson; Bao Lu; Craig Gerard; Mark Yorek
Journal:  Neuropharmacology       Date:  2010-09-16       Impact factor: 5.250

Review 5.  Small-fibre neuropathies--advances in diagnosis, pathophysiology and management.

Authors:  Janneke G Hoeijmakers; Catharina G Faber; Giuseppe Lauria; Ingemar S Merkies; Stephen G Waxman
Journal:  Nat Rev Neurol       Date:  2012-05-29       Impact factor: 42.937

6.  High-resolution axon reflex sweat testing for diagnosis of neuropathy.

Authors:  Adam Loavenbruck; Nathan Sit; Vincenzo Provitera; William Kennedy
Journal:  Clin Auton Res       Date:  2018-07-21       Impact factor: 4.435

7.  Combination of quercetin, cinnamaldehyde and hirudin protects rat dorsal root ganglion neurons against high glucose-induced injury through Nrf-2/HO-1 activation and NF-κB inhibition.

Authors:  Yue Shi; Xiao-Chun Liang; Hong Zhang; Qing Sun; Qun-Li Wu; Ling Qu
Journal:  Chin J Integr Med       Date:  2017-09-02       Impact factor: 1.978

Review 8.  Entrapment neuropathies in diabetes mellitus.

Authors:  Eugenia Rota; Nicola Morelli
Journal:  World J Diabetes       Date:  2016-09-15

Review 9.  Diabetic neuropathy: clinical features, etiology, and therapy.

Authors:  David Podwall; Clifton Gooch
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

10.  Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes.

Authors:  Viktor R Drel; Pal Pacher; Igor Vareniuk; Ivan A Pavlov; Olga Ilnytska; Valeriy V Lyzogubov; Seth R Bell; John T Groves; Irina G Obrosova
Journal:  Int J Mol Med       Date:  2007-12       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.